Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Icon Bioscience has completed enrollment in its Phase I clinical trial to assess the safety and efficacy of its lead product, IBI-20089, in patients with cystoid macular edema.
Subscribe to our email newsletter
This multi-site trial enrolled patients with cystoid macular edema associated with retinal vein occlusion and post operative cataract surgery.
IBI-20089 is a drug product based on Icon Bioscience’s (IBI) proprietary Verisome drug delivery platform technology, which is said to be optimally suited for application in the ophthalmic market.
According to the company, IBI-20089 is designed to last up to one year with a single intravitreal injection. It is administered as a standard intravitreal injection without the need for additional devices or surgical procedures.
Vernon Wong, founder of Icon Bioscience, said: “We are pleased to have reached this important milestone. Our preliminary data confirms the safety and efficacy of our lead product, IBI-20089, as well as the versatility and flexibility of our underlying Verisome drug delivery technology.”